Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | AKT2 | P31751 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1013817 | 0.98 | IDO1 (0.60) | IDO1TDP1LMNAMAPTNPC1 | |
| SCHEMBL6738366 | 0.80 | TSHR (0.76) | IDO1TDP1LMNAMAPTNPC1 | |
| SCHEMBL2018887 | 0.80 | AKT2 (0.52) | LMNAMAPTNPC1RAB9AAKT1 | |
| Iodide SCHEMBL30804629 | 0.78 | TSHR (0.73) | IDO1TDP1LMNAMAPTNPC1 | |
| SCHEMBL11392461 | 0.78 | TSHR (0.73) | IDO1TDP1LMNAMAPTNPC1 | |
| SCHEMBL28471286 | 0.78 | TSHR (0.73) | IDO1TDP1LMNAMAPTNPC1 | |
| SCHEMBL11392466 | 0.78 | TSHR (0.73) | IDO1TDP1LMNAMAPTNPC1 | |
| SCHEMBL30424015 | 0.78 | AKT2 (0.71) | AKT1AKT2 | |
| Iodide SCHEMBL28598177 | 0.78 | TSHR (0.73) | IDO1TDP1LMNAMAPTNPC1 | |
| SCHEMBL4585369 | 0.76 | IDO1 (0.56) | IDO1TDP1LMNAMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3985001-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER | SERVIER LAB (FR) | 2026-04-29 | — | — | EP | disclosed |
| US-20240059733-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-22 | — | — | US | disclosed |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-06-06 | — | — | US | disclosed |
| EP-3985001-A1 | PHARMACEUTICAL COMPOSITION USEFUL IN INHIBITING IDH1 | Les Laboratoires Servier SAS (FR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3447052-B1 | METHODS OF PREPARING NEW IDH1 INHIBITORS | LES LABORATOIRES SERVIER SAS (FR) | 2021-10-20 | — | — | EP | disclosed |
| US-11021515-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210024575-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2021-01-28 | — | — | US | disclosed |
| US-20200339626-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2020-10-29 | — | — | US | disclosed |
| US-10717764-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| CN-102105459-B | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2014-09-10 | — | — | CN | disclosed |
| WO-2014067962-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AG (DE) | 2014-05-08 | — | — | WO | disclosed |
| WO-2013107291-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | WO | disclosed |
| WO-2013107291-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | WO | disclosed |
| US-20130190249-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190249-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190249-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-25 | — | — | US | disclosed |
| US-8415479-B2 | Inhibitor of plasminogen activator inhibitor-1 | RENASCIENCE CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | RENASCIENCE CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2272822-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | Renascience CO., LTD. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339626-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | IDO1 2568/4885TDP1 301/4885LMNA 3349/4885 |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | SERPINE1, SERPINB1, SERPINC1 | IDO1 704/4885TDP1 1762/4885LMNA 525/4885 |
| US-11021515-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | IDO1 2568/4885TDP1 301/4885LMNA 3349/4885 |
| US-20210024575-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | IDO1 2568/4885TDP1 301/4885LMNA 3349/4885 |
| US-20240059733-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | IDO1 2568/4885TDP1 301/4885LMNA 3349/4885 |
| US-20130190249-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | IDO1 2766/4885TDP1 368/4885LMNA 1945/4885 |
| US-11667673-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | IDO1 2568/4885TDP1 301/4885LMNA 3349/4885 |
| US-10717764-B2 | Therapeutically active compounds and their methods of use | IDH1, IDH3B, IDH3A | IDO1 2568/4885TDP1 301/4885LMNA 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.